As of January 22, 2025, Intra-Cellular Therapies (ITCI) has a market cap of $13.51 billion USD. According to our data, Intra-Cellular Therapies is ranked No.1310 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $13.51 B |
52.26%
|
Dec 31, 2024 | $8.87 B |
16.62%
|
Dec 29, 2023 | $7.61 B |
35.34%
|
Dec 30, 2022 | $5.62 B |
1.11%
|
Dec 31, 2021 | $5.56 B |
64.59%
|
Dec 31, 2020 | $3.38 B |
-7.32%
|
Dec 31, 2019 | $3.65 B |
201.23%
|
Dec 31, 2018 | $1.21 B |
-21.34%
|
Dec 29, 2017 | $1.54 B |
-4.04%
|
Dec 30, 2016 | $1.60 B |
-71.95%
|
Dec 31, 2015 | $5.71 B |
204.76%
|
Dec 31, 2014 | $1.88 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Johnson & Johnson
JNJ
|
$347.78 B |
-0.005 M
|
USA
|
Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
Eli Lilly
LLY
|
$676.92 B |
0.020 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.86 B |
0.003 M
|
USA
|
AbbVie
ABBV
|
$300.53 B |
0.002 M
|
USA
|
Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
-0.001 M
|
USA
|
Gilead Sciences
GILD
|
$116.07 B |
0.004 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$75.23 B |
1.245 B
|
USA
|
Novartis
NVS
|
$197.43 B |
0.007 M
|
Switzerland
|
Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
GlaxoSmithKline
GSK
|
$68.38 B |
0.002 M
|
UK
|
Market Cap | = | ITCI Stock Price | * | ITCI Shares Outstanding |
= | $127.17 | * | 0.11 B | |
= | $13.51 B |